about
Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First MetastasisSafety of Infusing Ipilimumab Over 30 Minutes.Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterQuantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies.Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway.Reply to A. Indini et al
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Parisa Momtaz
@ast
Parisa Momtaz
@en
Parisa Momtaz
@es
Parisa Momtaz
@nl
Parisa Momtaz
@sl
type
label
Parisa Momtaz
@ast
Parisa Momtaz
@en
Parisa Momtaz
@es
Parisa Momtaz
@nl
Parisa Momtaz
@sl
prefLabel
Parisa Momtaz
@ast
Parisa Momtaz
@en
Parisa Momtaz
@es
Parisa Momtaz
@nl
Parisa Momtaz
@sl
P106
P21
P31
P496
0000-0002-3030-7615
P569
2000-01-01T00:00:00Z